Wellington Management

Wellington Management Company LLP, founded in 1928 and headquartered in Boston, Massachusetts, is a prominent investment management firm providing comprehensive solutions to institutional clients worldwide. The firm specializes in a diverse range of investment strategies, including equity, fixed income, multi-asset, and alternative investments, tailored to meet the unique return and risk objectives of its clients. Wellington Management employs a collaborative approach, leveraging proprietary research and analytical tools to identify opportunities and manage risks across global capital markets. The firm caters to a wide array of clients, including sovereign institutions, endowments, foundations, wealth managers, and insurance companies, spanning more than 50 countries. With a focus on long-term investment principles, Wellington Management fosters independent thought and debate within its teams, ensuring that resources are effectively utilized to deliver consistent results. The firm also emphasizes environmental, social, and governance (ESG) considerations in its research and investment processes, engaging with companies on key ESG topics.

Focus

Therapeutics Scale Stage Pharmaceuticals Late Stage Series C Show more

http://wellington.com

http://wellingtonmgt.com

https://crunchbase.com/organization/wellington-management

https://facebook.com/192813427434277

https://linkedin.com/company/wellington-management

https://pitchbook.com/profiles/advisor/13346-29

https://signal.nfx.com/firms/wellington-management

https://twitter.com/wellingtonmgt

https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=272858995

https://www.privateequityinternational.com/database/#/profile?id=5220

280 Congress Street, Boston, Massachusetts 02210, US

Pamela Choney

Partner and SVP

Anita M. Killian

Director, Partner, VP, Global Industry Analyst and Portfolio Manager

Past deals in Pharmaceuticals

Acrivon Therapeutics

Series B in 2021

Acrivon Therapeutics is a biotech company specializing in drug development through early clinical treatment success.

Ventyx Biosciences

Series B in 2021

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

NiKang Therapeutics

Series C in 2021

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Centessa Pharmaceuticals

Series A in 2021

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.

Nuvation Bio

Post in 2020

Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.

PMV Pharmaceutcals

Series D in 2020

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Blueprint Medicines

Series C in 2014

Blueprint Medicines Corporation focuses on developing small molecule kinase inhibitors aimed at treating genomic drivers in cancers, rare diseases, and enhancing cancer immunotherapy. The company is advancing several key drug candidates, including avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis and other mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, currently in Phase I clinical trials. Additionally, pralsetinib targets RET-altered non-small cell lung cancer and other solid tumors, while BLU-782 is being investigated for fibrodysplasia ossificans progressive. Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the development of personalized cancer therapies by leveraging insights into cancer genomics and utilizing a proprietary chemical library to identify new therapeutic compounds. The company collaborates with various partners, including Clementia Pharmaceuticals and Genentech, to enhance its research and development efforts.